Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy

Inclusion Criteria: * Willingly signs and dates an Informed Consent Form (ICF) that is approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), prior to the conduct of any study-specific procedures; * Is at least 18 years old; * Has a diagnosis of type 1 or type 2 diabetes and painful distal symmetric sensorimotor polyneuropathy; * Has experienced a minimum duration of PDN of at least 6 months; * Is on stable diabetic medication that is not expected to change during the study; * Has a worst pain intensity over the past 24 hours as a 4 or higher on a 0-10 numerical rating scale at Screening; * And is able to read and communicate meaningfully in English and comply with all study procedures Exclusion Criteria: * Has a psychiatric or psychological disorder that in the judgment of the Investigator would interfere with the completion of the study, confound the study results, or pose subject risk; * Has an uncontrolled, clinically significant medical condition that in the judgment of the Investigator may contraindicate use of pregabalin or participation in the study (e.g., hepatic, respiratory, or hematologic illness; cardiovascular disease; or symptomatic peripheral vascular disease); * Has experience as an investigator or a study staff member in clinical trials research in a role that involved direct patient contact; * Participated in any of the following studies: Analgesic Solutions Protocol # ALPMF.SOW.0007, Analgesic Solutions Protocol # ALPMF.SOW.0007.02, or Astellas Protocol # E05-CL-3004; * Has pain of other origin that might confound assessment of PDN; * Has major skin ulceration; * Has had an amputation other than toes; * Has a history of suicide attempt within the past 1 year; * Reports current suicidal ideation within the past 1month; * Has history of kidney disease that is likely to decrease creatinine clearance; * Has creatinine clearance below 60 as calculated by Cockroft-Gault equation for serum creatinine; * Has a history of drug or alcohol abuse within the past 1 year; * Has hypersensitivity, intolerance, or allergy to pregabalin or gabapentin; * Subject is pregnant, is considering becoming pregnant during the study, is breastfeeding or unwilling to use adequate birth control during the study; * Participated in another clinical trial within the past month; * Is involved in an ongoing or settled worker's compensation claim, disability, or litigation; * Has a known failure to respond to pregabalin or gabapentin at a clinically relevant dose due to either efficacy or tolerability; * Or has taken opioids on an as-needed basis within 1week of Screening, or has taken pregabalin or gabapentin within 30 days of screening. Subjects on stable doses opioids, antidepressants, non-steroidal anti-inflammatory drugs, or low-dose aspirin will be allowed to participate in the study